1. Scrip
  2. >>R&D

Alligator CEO Discusses Pipeline Additions, Milestone Expectations And The IO Deal Landscape

 
• By Jo Shorthouse

Alligator Bioscience’s Per Norlen discusses the latest addition to its pipeline, a first-in-class bispecific tumor-localized antibody targeting the checkpoint inhibitor CTLA-4.

Video interview
• Source: Shutterstock

Speaking to Scrip on the sidelines of BIO-Europe in Copenhagen Alligator Bioscience AB’s CEO, Per Norlen, described the latest addition to the small Swedish cancer specialist’s pipeline, a bispecific antibody, ATOR-1144, which is a dual immune activator targeting CTLA-4 and GITR.

ATOR-1144 works through several pathways, including activation of T-cells, depletion of regulatory T-cells, and activation of NK cells, for enhanced...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

Profit-Sharing AI Model Proposed To Boost Korean Drug R&D

 
• By Jung Won Shin

A differentiated profit-sharing model to accelerate the use of AI in drug development using clinical and patient data is being proposed in South Korea, but the idea faces multiple practical challenges

Sarepta Market Dynamics For Elevidys Imperiled By Second Patient Death

 
• By Joseph Haas

With two deaths in non-ambulatory DMD patients, Sarepta is attempting damage control and will ask the US FDA to advise, setting up a possible confrontation with CBER director Prasad.

Supernus Secures Sage With CVR-Supported Deal

 
• By Jessica Merrill

Supernus agreed to pay $561m upfront plus a contingent value right that could add $234m to buy Sage, topping a previously rejected offer from Biogen.